Puma Biotechnology Inc

The asset exhibits a classic blow-off top with a long upper wick and high-volume exhaustion in Stage 2, suggesting medium-term reversal risk; short-term rejection at resistance and overbought conditions favor immediate bearish engagement through a sell now posture, targeting the recent resistance zone with rejection-based execution.

• ↑FY26 Nearlink revenue guidance of $202–206M, up vs prior
• ↑Neratinib new prescriptions increased ~25% quarter-over-quarter
• ↓Q1 2026 product revenue fell to $42M from $59.9M in Q4 2025